Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease

Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Study ID
NCT07464587
Phase
PHASE3
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
40 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • TQC3721 Suspension for Inhalation — DRUG
    TQC3721 suspension for inhalation is a Phosphodiesterase3/4 (PDE3/4) inhibitor.

Study Details

To evaluate the safety of inhaled TQC3721 Suspension in patients with moderate to severe Chronic Obstructive Pulmonary Disease

Key Dates

First listed
Mar 11, 2026
Start date
Mar 31, 2026
Status verified
Mar 2026
Primary completion
Feb 28, 2027
Completion
Apr 30, 2027

Study Design

Enrollment
800 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: TQC3721 Suspension for Inhalation (Twice a day)
    Queue A: One TQC3721 suspension for inhalation (6mg/2ml), twice a day for 24 weeks. Queue B: One TQC3721 suspension for inhalation (6mg/2ml), twice a day for 12 weeks.

Primary Outcome Measure

Adverse event rate [ Time Frame: Queue A: Extended study period: Weeks 24-50; Queue B: At week 12 of treatment ]

Central Contacts

Find similar trials

Nationwide
COPD trialsPulmonology trialsLung disease trials

Related Studies